MedPath

Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)

Phase 1
Conditions
Huntington Disease
Interventions
Radiation: Far Infrared Radiation
Registration Number
NCT00675077
Lead Sponsor
GAAD Medical Research Institute Inc.
Brief Summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.

This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Detailed Description

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
5
Inclusion Criteria
  • People with HD
Exclusion Criteria
  • None

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Far Infrared RadiationRadiation: Far Infrared Radiation (5μm to 20μm wavelength)
Primary Outcome Measures
NameTimeMethod
Treatment of people with HD2 years
Secondary Outcome Measures
NameTimeMethod
Rehabilitation of people with HD2 Years

Trial Locations

Locations (1)

The Centre for Incurable Diseases

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath